The year 2019 had its share of disappointing drug trials in Alzheimer disease, leading many to question whether anti-amyloid therapies were the optimal strategy. But that view may have shifted with controversial developments later in the year. Read More
Latest News
Antidepressants – mixed scorecard in 2019
December 19, 2019The year 2019 saw two novel antidepressants receive FDA approval amid a series of disappointing phase III trials.
Sequencing MS therapies – a changing landscape
December 17, 2019Comment by Dr. Virender Bhan – Senior neurologist, Burnaby/Vancouver, BC, Canada.
NeuroSens recently posted a survey on sequencing disease-modifying therapies (DMTs) in multiple sclerosis to investigate whether clinicians’ approaches have changed in the past 2-3 years. The current survey was a follow-up to a series of surveys conducted over a one-year period ending in December 2017 that accompanied an 8-part article on sequencing. (For a summary of those results see Are opinions changing on changing therapies in MS?, NeuroSens, October 22, 2019). Read More
Importance of vaccination: the Sick Santa model
December 12, 2019A researcher in Japan has raised a seasonally timely question: what if Santa Claus had a communicable disease as he made his rounds (Furuse Y. Med J Aust 2019;211:523-524)?